Addressing these knowledge gaps through human trials will be essential for assessing the therapeutic potential of strategies centered on the METTL3-NEDD4L-TFRC axis against cerebral ischemia–reperfusion injury. This evidence concerns the gene METTL3 and Cerebral ischemia.